13 January 2024 - In the pivotal Phase 3 TRANSFORM trial, Breyanzi demonstrated a significant improvement in event-free survival over standard of care with a well-established and manageable safety profile.

Bristol Myers Squibb Canada is pleased to announce Health Canada's approval of Breyanzi (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy, and who are candidates for autologous hematopoietic stem cell transplantation.

The Health Canada Notice of Compliance was received on 25 September 2024.

Read BMS press release